Trial Profile
An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 03 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 27 Aug 2018 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 27 Aug 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.